{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:16:22Z","timestamp":1789766182125,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier","isbn-type":[{"value":"9780128211182","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.irn.2020.03.032","type":"book-chapter","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T09:07:04Z","timestamp":1591693624000},"page":"213-230","source":"Crossref","is-referenced-by-count":8,"title":["Placebo effect in subjects with cognitive impairment"],"prefix":"10.1016","member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2020.03.032_bb0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","article-title":"2019 Alzheimer's disease facts and figures","volume":"15","author":"Alzheimers Disease Facts and Figures","year":"2019","journal-title":"Alzheimers & Dementia"},{"issue":"9","key":"10.1016\/bs.irn.2020.03.032_bb0015","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.032_bb0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/npp.2010.81","article-title":"How placebos change the patients brain","volume":"36","author":"Benedetti","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/bs.irn.2020.03.032_bb0025","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"key":"10.1016\/bs.irn.2020.03.032_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuroscience.2015.08.017","article-title":"The placebo effect: From concepts to genes","volume":"307","author":"Colagiuri","year":"2015","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.032_bb0035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10928-014-9375-z","article-title":"An updated Alzheimer's disease progression model: Incorporating non-linearity, beta regression, and a third-level random effect in NONMEM","volume":"41","author":"Conrado","year":"2014","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.032_bb0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40495-016-0066-x","article-title":"Disease progression Modeling: Key concepts and recent developments","volume":"2","author":"Cook","year":"2016","journal-title":"Current Pharmacology Reports"},{"issue":"7","key":"10.1016\/bs.irn.2020.03.032_bb0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.euroneuro.2008.03.002","article-title":"Imaging the placebo response: A neurofunctional review","volume":"18","author":"Faria","year":"2008","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.032_bb0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","article-title":"Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimers disease: A longitudinal study","volume":"17","author":"Gordon","year":"2018","journal-title":"The Lancet Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2020.03.032_bb0055","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jalz.2016.05.005","article-title":"Big data to smart data in Alzheimers disease: Real-world examples of advanced modeling and simulation","volume":"12","author":"Haas","year":"2016","journal-title":"Alzheimers & Dementia"},{"issue":"23","key":"10.1016\/bs.irn.2020.03.032_bb0060","doi-asserted-by":"crossref","first-page":"11466","DOI":"10.1073\/pnas.89.23.11466","article-title":"Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine","volume":"89","author":"Holford","year":"1992","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"23","key":"10.1016\/bs.irn.2020.03.032_bb0065","doi-asserted-by":"crossref","first-page":"11471","DOI":"10.1073\/pnas.89.23.11471","article-title":"Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine","volume":"89","author":"Holford","year":"1992","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.032_bb0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jalz.2009.05.665","article-title":"Disease progression meta-analysis model in Alzheimers disease","volume":"6","author":"Ito","year":"2010","journal-title":"Alzheimers & Dementia"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.032_bb0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3233\/JAD-130575","article-title":"Understanding placebo responses in Alzheimers disease clinical trials from the literature meta-data and CAMD database","volume":"37","author":"Ito","year":"2013","journal-title":"Journal of Alzheimers Disease"},{"issue":"2","key":"10.1016\/bs.irn.2020.03.032_bb0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimers disease: An updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.032_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.032_bb0090","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: Implications for sequence of pathological events in Alzheimers disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.032_bb0095","first-page":"5","article-title":"PDUFA VI: It is time to unleash the full potential of model-informed drug development","volume":"8","author":"Jain","year":"2018","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2020.03.032_bb0100","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1007\/s11095-006-9048-8","article-title":"Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimers disease","volume":"23","author":"Lockwood","year":"2006","journal-title":"Pharmaceutical Research"},{"issue":"S2","key":"10.1016\/bs.irn.2020.03.032_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00761-018-0358-3","article-title":"Real-world evidence research based on big data","volume":"24","author":"Maissenhaelter","year":"2018","journal-title":"Der Onkologe"},{"issue":"12","key":"10.1016\/bs.irn.2020.03.032_bb0110","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/gim.2017.59","article-title":"Sharing data under the 21st century cures act","volume":"19","author":"Majumder","year":"2017","journal-title":"Genetics in Medicine"},{"issue":"6","key":"10.1016\/bs.irn.2020.03.032_bb0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/cts.12488","article-title":"The role of public\u2013private partnerships in catalyzing the critical path","volume":"10","author":"Maxfield","year":"2017","journal-title":"Clinical and Translational Science"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.032_bb0120","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pharmthera.2013.07.009","article-title":"Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions","volume":"140","author":"Murray","year":"2013","journal-title":"Pharmacology & Therapeutics"},{"issue":"10","key":"10.1016\/bs.irn.2020.03.032_bb0125","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jalz.2014.11.005","article-title":"Development of a unified clinical trial database for Alzheimers disease","volume":"11","author":"Neville","year":"2015","journal-title":"Alzheimers & Dementia"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.032_bb0130","doi-asserted-by":"crossref","DOI":"10.1007\/BF00193473","article-title":"The effect of tacrine and lecithin in Alzheimers disease","volume":"47","author":"Peace","year":"1994","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"12","key":"10.1016\/bs.irn.2020.03.032_bb0135","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","article-title":"Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimers disease in the presenilin 1 E280A kindred: A case-control study","volume":"11","author":"Reiman","year":"2012","journal-title":"The Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.032_bb0140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10928-012-9263-3","article-title":"Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: A beta regression meta-analysis","volume":"39","author":"Rogers","year":"2012","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.032_bb0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.16","article-title":"The future is now: Model-based clinical trial design for Alzheimers disease","volume":"97","author":"Romero","year":"2014","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"5","key":"10.1016\/bs.irn.2020.03.032_bb0150","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0091270011405497","article-title":"An improved model for disease progression in patients from the Alzheimers disease neuroimaging initiative","volume":"52","author":"Samtani","year":"2012","journal-title":"The Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2020.03.032_bb0155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimers disease: An appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"Journal of Internal Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2020.03.032_bb0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimers disease: A prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2020.03.032_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.59.090506.155819","article-title":"The FDA critical path initiative and its influence on new drug development","volume":"59","author":"Woodcock","year":"2008","journal-title":"Annual Review of Medicine"}],"container-title":["International Review of Neurobiology","Placebo Effects in Neurologic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774220300635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774220300635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:11:38Z","timestamp":1758748298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774220300635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128211182"],"references-count":32,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2020.03.032","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}